Omega Therapeutics CFO Joshua Reed to depart May 31; Barbara Chan named successor

Omega Therapeutics, Inc.

Joshua Reed's employment terminated effective May 31, 2024; severance and extended option exercisability.
Barbara Chan, SVP Finance, appointed principal financial officer and principal accounting officer effective May 31.
Chan also becomes Treasurer; has been at Omega since May 2020.
Prior role: VP Finance and CAO at Aegerion Pharmaceuticals (2016-2019).
Chan holds B.S. and M.S. in Accounting and Taxation from Bentley University.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Barbara Chan

principal financial officer and principal accounting officer

Omega Therapeutics, Inc.

Effective: 2024-05-31
Filed: April 16, 2024, 7:59 PM ET

On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company’s Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.

Departed

Joshua Reed

Chief Financial Officer

Omega Therapeutics, Inc.

Effective: 2024-05-31
Successor: Barbara Chan
Filed: April 16, 2024, 7:59 PM ET

On April 10, 2024, Omega Therapeutics, Inc. (the “Company”) and Joshua Reed, the Company’s Chief Financial Officer, agreed to terminate his employment effective as of May 31, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Barbara Chan was appointed as principal financial officer and principal accounting officer at Omega Therapeutics, Inc..

Action: designated
Role: principal financial officer and principal accounting officer

Exact text from the filing

On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company’s Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Reed was terminated as Chief Financial Officer at Omega Therapeutics, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On April 10, 2024, Omega Therapeutics, Inc. (the “Company”) and Joshua Reed, the Company’s Chief Financial Officer, agreed to terminate his employment effective as of May 31, 2024

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-044795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.